FT
Flare TherapeuticsFlare Therapeutics is a clinical-stage biotech developing small-molecule drugs that target transcription factors, including a first-in-class ARON-targeting degrader for prostate cancer.
2 Pulse stories
TB
Triveni BioTriveni Bio develops genetics-informed antibody and bispecific therapeutics for immunological and inflammatory diseases.
2 Pulse stories
Total Raised
$290M
$272M
Flare TherapeuticsTriveni Bio
Last ValuationNot disclosed
Biotech
Sector
Biotech
2021
Founded
2023
Cambridge, Massachusetts
HQ
Waltham, Massachusetts
Private
Status
Private
Flare Therapeutics investors
Third Rock VenturesNextech InvestPfizer VenturesBoxer CapitalGordonMD Global InvestmentsInvusCasdin CapitalEli Lilly and Company
Triveni Bio investors
Atlas VentureCormorant Asset ManagementAscenta CapitalJanus Henderson InvestorsDeep Track CapitalOrbiMedViking Global InvestorsFidelity Management & Research
Data from Value Add Pulse coverage and company research — see the full threads for Flare Therapeutics and Triveni Bio.